Journal article
Non-verbal episodic memory deficits in primary progressive aphasias are highly predictive of underlying amyloid pathology
S Ramanan, E Flanagan, CE Leyton, VL Villemagne, CC Rowe, JR Hodges, M Hornberger
Journal of Alzheimer S Disease | Published : 2016
DOI: 10.3233/JAD-150752
Abstract
Diagnostic distinction of primary progressive aphasias (PPA) remains challenging, in particular for the logopenic (lvPPA) and nonfluent/agrammatic (naPPA) variants. Recent findings highlight that episodic memory deficits appear to discriminate these PPA variants from each other, as only lvPPA perform poorly on these tasks while having underlying amyloid pathology similar to that seen in amnestic dementias like Alzheimer's disease (AD). Most memory tests are, however, language based and thus potentially confounded by the prevalent language deficits in PPA. The current study investigated this issue across PPA variants by contrasting verbal and non-verbal episodic memory measures while controll..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by Australian Research Council (ARC) Centre of Excellence in Cognition and its Disorders
Funding Acknowledgements
This work was supported in part by funding to ForeFront, a collaborative research group dedicated to the study of frontotemporal dementia and motor neuron disease, from the National Health and Medical Research Council (NHMRC) (APP1037746) and the Australian Research Council (ARC) Centre of Excellence in Cognition and its Disorders (CE11000102).MH is supported by Alzheimer's Research UK, the Wellcome Trust and the Newton Trust. JRH is supported by NHMRC program and ARC Centre of Excellence in Cognition and its Disorders. CEL is supported by DVC postdoctoral Fellowship, University of Sydney, Australia. VLV is a recipient of a NHMRC Research Fellowship and received speaker's honoraria from GE Healthcare, AstraZeneca, and Piramal Imaging, and consulting honoraria from Novartis and Bayer Healthcare. CR is a recipient of grants from GE Healthcare, Avid Radiopharmaceuticals, Piramal Imaging, and Navidea, NHMRC research grant, and speaker's honoraria from GE Healthcare, Piramal Imaging, and AstraZeneca.